Skip to main content

Cellectis S.A.

CLLS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001627281

No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Cellectis S.A. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of CLLS: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders5751−6
Shares15.2M12.3M−2.92M (−19.2%)
Value$123.7M$55.8M−$68.0M (−54.9%)

New holders (9)

Institutions that held Cellectis S.A. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to CLLS in Q1 2022
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP131,848$599.0K0.00%
Oppenheimer & Co Inc74,654$339.0K0.01%
Two Sigma Advisers, LP54,800$249.0K0.00%
Goldman Sachs Group Inc53,223$242.0K0.00%
Old Mission Capital LLC17,068$77.0K0.00%
Princeton Capital Management LLC10,929$50.0K0.02%
Money Concepts Capital Corp515$2.00K0.00%
Assetmark, Inc360$2.00K0.00%
TCWP LLC325$1.00K0.00%

Sold out (15)

Institutions that held Cellectis S.A. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of CLLS in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
ARK Investment Management LLCSuperinvestorARK Invest2,941,556$23.9M
Nikko Asset Management Americas, Inc.627,910$5.40M
Sumitomo Mitsui Trust Holdings, Inc.627,910$5.10M
683 Capital Management, LLC352,638$2.86M
Exchange Traded Concepts, LLC347,174$2.82M
Legal & General Group Plc337,201$2.74M
Eqis Capital Management, Inc.104,063$845.0K
Bellevue Group AG82,500$670.0K
Citadel Advisors LLC42,418$344.0K
Susquehanna International Group, LLP22,287$181.0K
Geneos Wealth Management Inc.10,000$81.0K
Signaturefd, LLC3,801$31.0K
Barclays PLC2,324$19.0K
Zurcher Kantonalbank (Zurich Cantonalbank)1,933$16.0K
Lindbrook Capital, LLC1,529$12.0K